Denali Therapeutics Inc (DNLI)
20.24
-0.62
(-2.97%)
USD |
NASDAQ |
May 16, 16:00
20.48
+0.24
(+1.19%)
After-Hours: 20:00
Denali Therapeutics Enterprise Value: 1.950B for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 1.950B |
| May 15, 2024 | 2.038B |
| May 14, 2024 | 1.880B |
| May 13, 2024 | 1.815B |
| May 10, 2024 | 1.674B |
| May 09, 2024 | 1.726B |
| May 08, 2024 | 1.758B |
| May 07, 2024 | 1.466B |
| May 06, 2024 | 1.507B |
| May 03, 2024 | 1.507B |
| May 02, 2024 | 1.460B |
| May 01, 2024 | 1.368B |
| April 30, 2024 | 1.265B |
| April 29, 2024 | 1.287B |
| April 26, 2024 | 1.263B |
| April 25, 2024 | 1.196B |
| April 24, 2024 | 1.281B |
| April 23, 2024 | 1.359B |
| April 22, 2024 | 1.342B |
| April 19, 2024 | 1.344B |
| April 18, 2024 | 1.429B |
| April 17, 2024 | 1.461B |
| April 16, 2024 | 1.535B |
| April 15, 2024 | 1.606B |
| April 12, 2024 | 1.666B |
| Date | Value |
|---|---|
| April 11, 2024 | 1.796B |
| April 10, 2024 | 1.689B |
| April 09, 2024 | 1.834B |
| April 08, 2024 | 1.777B |
| April 05, 2024 | 1.827B |
| April 04, 2024 | 1.769B |
| April 03, 2024 | 1.824B |
| April 02, 2024 | 1.825B |
| April 01, 2024 | 1.993B |
| March 28, 2024 | 1.888B |
| March 27, 2024 | 1.923B |
| March 26, 2024 | 1.796B |
| March 25, 2024 | 1.795B |
| March 22, 2024 | 1.759B |
| March 21, 2024 | 1.956B |
| March 20, 2024 | 1.997B |
| March 19, 2024 | 1.890B |
| March 18, 2024 | 1.826B |
| March 15, 2024 | 1.832B |
| March 14, 2024 | 1.778B |
| March 13, 2024 | 1.942B |
| March 12, 2024 | 1.923B |
| March 11, 2024 | 2.054B |
| March 08, 2024 | 1.946B |
| March 07, 2024 | 1.889B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
902.83M
Minimum
Oct 18 2019
10.26B
Maximum
Dec 22 2020
3.070B
Average
2.542B
Median
Enterprise Value Benchmarks
| Halozyme Therapeutics Inc | 6.814B |
| AIM ImmunoTech Inc | 7.080M |
| Perspective Therapeutics Inc | 890.47M |
| Protalix BioTherapeutics Inc | 57.71M |
| Armata Pharmaceuticals Inc | 189.99M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -101.80M |
| Total Expenses (Quarterly) | 132.25M |
| EPS Diluted (Quarterly) | -0.68 |
| Earnings Yield | -4.74% |
| Normalized Earnings Yield | -4.792 |